TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $31.83 Average Target Price from Analysts

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have been assigned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $31.83.

Several research analysts recently issued reports on the company. B. Riley upped their target price on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and set a $49.00 price objective on shares of TG Therapeutics in a report on Tuesday, August 6th. LADENBURG THALM/SH SH lifted their target price on shares of TG Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, May 2nd. Finally, The Goldman Sachs Group upped their price target on shares of TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th.

Hedge Funds Weigh In On TG Therapeutics

A number of institutional investors have recently modified their holdings of TGTX. Pingora Partners LLC purchased a new position in shares of TG Therapeutics during the 4th quarter valued at approximately $27,000. Ashton Thomas Private Wealth LLC acquired a new stake in TG Therapeutics during the second quarter valued at $35,000. DekaBank Deutsche Girozentrale purchased a new position in TG Therapeutics in the first quarter valued at $58,000. Lazard Asset Management LLC acquired a new position in shares of TG Therapeutics in the first quarter worth about $91,000. Finally, nVerses Capital LLC boosted its stake in shares of TG Therapeutics by 34.9% during the 2nd quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $103,000 after acquiring an additional 1,500 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

Shares of NASDAQ:TGTX opened at $25.19 on Friday. The firm has a 50 day moving average of $19.43 and a 200 day moving average of $16.89. The company has a quick ratio of 2.84, a current ratio of 3.62 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $3.89 billion, a price-to-earnings ratio of 109.52 and a beta of 2.23. TG Therapeutics has a 52 week low of $6.46 and a 52 week high of $25.29.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. The business had revenue of $73.47 million for the quarter, compared to the consensus estimate of $65.92 million. TG Therapeutics had a return on equity of 31.34% and a net margin of 14.24%. The business’s revenue was up 357.0% compared to the same quarter last year. During the same period last year, the business posted ($0.34) EPS. On average, sell-side analysts predict that TG Therapeutics will post -0.01 earnings per share for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.